Skip to main content
. Author manuscript; available in PMC: 2019 Nov 13.
Published in final edited form as: Nat Neurosci. 2019 May 13;22(6):897–908. doi: 10.1038/s41593-019-0399-y

Fig. 4: Ascl1 and Neurog2 binding results in differential chromatin accessibility and enhancer activity.

Fig. 4:

a, Time-series ATAC-seq heatmaps displaying the gain of accessibility at the Ascl1 and Neurog2 binding sites (n=2). b, Metagene plots of accessibility (ATAC-seq reads) at the differentially bound and shared sites of Ascl1 and Neurog2 that were previously active (left) or previously inactive (right) before induction of the TFs (0h or EB t=0). c, H3K27ac ChIP-seq at Ascl1 and Neurog2 binding sites at 48h shows the gain of enhancer activity at the bound sites in comparison to 0h (n=2). d, Metagene plots of H3K27ac ChIP-seq at the differentially bound and shared sites of Ascl1 and Neurog2 that were previously active (left) or previously inactive (right) before the induction of the TFs (0h or EB t=0).